Ruboxistaurin
Sponsors
Chromaderm, Inc., Brigham and Women's Hospital, University of Tennessee
Conditions
Diabetes MellitusDiabetes Mellitus, Type 1Diabetic Macular EdemaDiabetic NeuropathyDiabetic RetinopathyHeart FailureType 1 Diabetes MellitusType 2 Diabetes Mellitus
Phase 1
Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
CompletedNCT00552227
Start: 2002-09-30End: 2005-07-31Updated: 2016-07-26
Ruboxistaurin in New York Heart Failure Classification III-IV Patients
WithdrawnNCT02769611
Start: 2017-06-28End: 2022-01-01Updated: 2022-06-06
Phase 2
The Effect of Ruboxistaurin on Small Fiber Function
CompletedNCT00190970
Start: 2004-10-31End: 2005-11-30Target: 52Updated: 2016-07-26
Effect of LY333531 on Vascular and Neural Functions
CompletedNCT00482976
Start: 2003-12-31End: 2005-03-31Updated: 2016-07-26
Signaling Mechanisms and Vascular Function in Diabetes Mellitus
CompletedNCT00761852
Start: 1999-05-31End: 2007-10-31Target: 30Updated: 2008-09-30
Phase 3
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
CompletedNCT00090519
Start: 2004-02-29End: 2010-04-30Updated: 2016-10-06
Effect of Ruboxistaurin on Clinically Significant Macular Edema
CompletedNCT00133952
Start: 2005-08-31End: 2011-07-31Updated: 2016-10-06
Treatment for Completers of the Study B7A-MC-MBCM
CompletedNCT00266695
Start: 2006-01-31End: 2008-08-31Updated: 2016-10-06
Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus
CompletedNCT00297401
Start: 2006-03-31End: 2007-11-30Updated: 2016-08-29
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
CompletedNCT00604383
Start: 2001-03-31End: 2005-06-30Updated: 2016-10-06